The ILKAP Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population in which the ILKAP gene has been disrupted in Jurkat T-cells. This product provides a heterogeneous knockout pool, avoiding clonal artifacts and enabling robust functional analysis of ILKAP-dependent processes. The polyclonal format offers a cost-effective model for investigating the role of this phosphatase in integrin-mediated signaling and T-cell biology.
Jurkat cells are an immortalized human T-lymphocyte line derived from an acute T-cell leukemia patient. Widely used for studying T-cell receptor signaling, leukemogenesis, and immune cell function, they offer a well-characterized background with rapid growth and ease of genetic manipulation. Their relevance to adhesion and survival pathways makes them an appropriate host for ILKAP knockout studies.
ILKAP encodes a serine/threonine phosphatase that specifically dephosphorylates integrin-linked kinase (ILK) at regulatory sites within the ILK-PINCH-parvin complex. This complex connects integrins to the cytoskeleton and propagates signals through AKT, GSK3??, and ??-catenin. By targeting ILK, ILKAP serves as a critical brake on integrin-induced cell adhesion, migration, and survival programs. ILKAP activity is stimulated by integrin engagement, positioning it in a negative feedback loop that shapes dynamic responses to extracellular matrix cues. Its loss thereby permits sustained ILK-dependent pathway activation.
Within Jurkat T-cells, ILKAP deletion is expected to elevate ILK-mediated phosphorylation events, enhancing AKT signaling and ??-catenin stabilization. This may mimic aspects of leukemic transformation, particularly in contexts where integrin?Ccytoskeleton crosstalk drives aberrant adhesion and proliferation. The model allows dissection of how phosphatase dysfunction contributes to T-cell leukemia biology and microenvironmental interactions.
These cells are suitable for investigating integrin signaling, cell adhesion, migration, and phosphatase function in cancer and leukemia. Compatible assays include cell adhesion and transwell migration tests, western blotting for phospho-AKT and phospho-GSK3??, integrin flow cytometry, co-immunoprecipitation of ILKAP-ILK, apoptosis induction, and ??-catenin/TCF reporter assays. They also support screening for ILK pathway modulators and validation of downstream ILKAP targets in T-cell biology. For further information or to discuss specific application requirements, please contact Ascent Research.
